Featured Posts
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
City Journal
The FTC Jettisons Economics—and Law
The Federal Trade Commission is stepping up its pursuit of its new favorite bogeyman: Pharmacy Benefit Managers. Two months ago, the FTC issued an …
Search Posts
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
City Journal
The FTC Jettisons Economics—and Law
The Federal Trade Commission is stepping up its pursuit of its new favorite bogeyman: Pharmacy Benefit Managers. Two months ago, the FTC issued an …
HeartLand Daily News
FDA Hid COVID Shot Side Effects—Congressional Report
Heartland Daily News cited CEI on COVID public health concerns Joel Zinberg, M.D., senior fellow at the Competitive Enterprise Institute and director of the Public…
The Wall Street Journal
The FTC Goes Evidence-Free
Through three years of Lina Khan’s leadership, the Federal Trade Commission has suffered an unprecedented streak of high-profile court defeats. That’s because the agency regularly makes…
News Release
New FTC study on drug costs fails to conduct empirical analysis of market conditions
The Federal Trade Commission (FTC) release a new study today claiming Pharmacy Benefit Managers (PBMs) are responsible for higher drug costs. FTC Commissioner Melissa Holyoak…